Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Raw Materials (2018 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Raw Materials for 6 consecutive years, with $31.9 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Raw Materials rose 76.24% year-over-year to $31.9 million, compared with a TTM value of $31.9 million through Mar 2025, up 76.24%, and an annual FY2024 reading of $33.7 million, up 56.74% over the prior year.
  • Raw Materials was $31.9 million for Q1 2025 at Neurocrine Biosciences, down from $33.7 million in the prior quarter.
  • Across five years, Raw Materials topped out at $33.7 million in Q4 2024 and bottomed at $18.1 million in Q1 2024.
  • Average Raw Materials over 3 years is $25.0 million, with a median of $22.6 million recorded in 2023.
  • The sharpest move saw Raw Materials skyrocketed 56.74% in 2024, then skyrocketed 76.24% in 2025.
  • Year by year, Raw Materials stood at $21.5 million in 2023, then skyrocketed by 56.74% to $33.7 million in 2024, then decreased by 5.34% to $31.9 million in 2025.
  • Business Quant data shows Raw Materials for NBIX at $31.9 million in Q1 2025, $33.7 million in Q4 2024, and $23.7 million in Q3 2024.